Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxalta Completes Acquisition of ONCASPAR Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxalta Completes Acquisition of ONCASPAR Portfolio

Brings significant growth potential of at least $500 million

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta Inc. (formerly Baxter BioScience) has completed the acquisition of the ONCASPAR (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A, for approximately $900 million. ONCASPAR, for the treatment of acute lymphoblastic leukemia (ALL), is a novel investigational biologic calaspargase pegol, with a established global clinical and commercial resources.

ONCASPAR is a biologic cancer therapy used as a component of multi-agent chemotherapeutic regimens to treat acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the white blood cells responsible for more than 80% of childhood leukemia cases. It’s primarily marketed in the U.S., Germany, Poland and certain other countries and is currently under review with the EMA. Annual sales of ONCASPAR are estimated at $100 million, with significant growth potential starting in 2016, with sales potential of at least $500 million.

“Our focus at Baxalta is building on our rich expertise and capabilities in orphan diseases and complex therapeutics to address significant unmet needs for patients with a variety of challenging diseases, including leukemia,” said Ludwig Hantson, chief executive officer and president, Baxalta. “With the addition of ONCASPAR, a very well recognized and effective component of standard chemotherapy, we’re now positioned to introduce innovation in areas where the community is still seeking meaningful new solutions.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics